X-101403924-A-G
Variant summary
Our verdict is Pathogenic. The variant received 13 ACMG points: 13P and 0B. PM1PM2PM5PP2PP3_StrongPP5_Moderate
The NM_000169.3(GLA):c.256T>C(p.Tyr86His) variant causes a missense change involving the alteration of a conserved nucleotide. The variant was absent in control chromosomes in GnomAD project. In-silico tool predicts a pathogenic outcome for this variant. Variant has been reported in ClinVar as Pathogenic (★). Another variant affecting the same amino acid position, but resulting in a different missense (i.e. Y86D) has been classified as Likely pathogenic.
Frequency
Consequence
NM_000169.3 missense
Scores
Clinical Significance
Conservation
Publications
Genome browser will be placed here
ACMG classification
Our verdict: Pathogenic. The variant received 13 ACMG points.
Transcripts
RefSeq
| Gene | Transcript | HGVSc | HGVSp | Effect | Exon rank | MANE | Protein | UniProt |
|---|---|---|---|---|---|---|---|---|
| GLA | NM_000169.3 | c.256T>C | p.Tyr86His | missense_variant | Exon 2 of 7 | ENST00000218516.4 | NP_000160.1 |
Ensembl
Frequencies
GnomAD3 genomes Cov.: 24
GnomAD4 exome Cov.: 30
GnomAD4 genome Cov.: 24
ClinVar
Submissions by phenotype
Fabry disease Pathogenic:2
GLA p.Tyr86His (c.256T>C) is a missense variant that changes the amino acid at residue 86 from Tyrosine to Histidine. This variant has been observed in at least one proband affected with Fabry disease (PMID:26415523;32023956;28723748;19925283;19843083). At least one functional study has demonstrated a substantial alteration in protein function relative to the wild-type (PMID:32023956;26415523;27657681). It is absent or not present at a significant frequency in gnomAD. In silico models agree that this variant is possibly or probably damaging. In conclusion, we classify GLA p.Tyr86His (c.256T>C) as a pathogenic variant.
Migalastat response Other:1
Pharmacological Chaperone response: no
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at